Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#What is the Projected CAGR for the Cancer Cachexia Market Size from 2025 to 2034?#_x000D_
In the past few years, the market size for cancer cachexia has seen robust growth. The market, which was worth $2.47 billion in 2024, is expected to rise to $2.6 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of 5.3%. This growth in the earlier period can be credited to heightened understanding of the biology of cancer, wide prevalence of the disease, increasing aged population, enhanced emphasis on patient-oriented care, wider range of treatment options, and increased consciousness among providers of healthcare services._x000D_
_x000D_
The market size of cancer cachexia is anticipated to witness significant expansion in the coming years. It is projected to increase to$3.21 billion in 2029 with a compound annual growth rate (CAGR) of 5.5%.” Factors contributing to this growth for the forecast period include heightened awareness regarding cachexia management, growing elderly populace, an increase in the uptake of innovative therapeutic strategies, escalating healthcare spending, and supportive governmental initiatives. The forecast period will also see key trends such as heightened research and development activities, broadening therapeutic alternatives, improved detection rates, adoption of new treatment methods, and advancements in supportive care approaches._x000D_
_x000D_
#Download a free sample to assess the report’s scope and structure:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp_x000D_
_x000D_
#What Are the Major Market Drivers Behind the Rising Adoption of Cancer Cachexia Market?#_x000D_
The cancer cachexia market’s expansion is predicted to be fueled by the escalating occurrence of cancer. Cancer is a condition characterized by uncontrolled growth of abnormal cells in the body, which results in tumor formation and disrupts ordinary bodily processes. Multiple factors are believed to contribute to the incidence of cancer, such as changes in lifestyle, environmental factors, an aging population, genetic susceptibility, enhanced diagnostic techniques for early detection, and heightened awareness leading more individuals to seek medical help. Progress in medical technology and a deeper comprehension of cancer and its complications are leading to more frequent cancer cachexia diagnoses and reports. Healthcare practitioners are honing their skills to spot symptoms of cachexia, which allows for prompt interventions and commencement of treatment. For example, data from the Australian Bureau of Statistics in December 2023 showed that around 1.8% of the population, equaling approximately 456,200 people, were reported to have cancer in Australia in 2022. Additionally, according to the National Cancer Institute in the United States in May 2024, it is anticipated that in 2024, around 2,001,140 new cancer instances will be identified in the U.S., with an expected 611,720 cancer-related deaths. In 2022, almost 20 million new cases and 9.7 million cancer-related deaths were reported globally. By 2040, the projected new cancer cases annually are expected to surge to 29.9 million, with cancer-related deaths reaching 15.3 million. Consequently, the escalating incidence of cancer is stimulating the cancer cachexia market’s growth._x000D_
_x000D_
#Which Key Market Segments Comprise the Cancer Cachexia Market and Drive Its Revenue Growth?#_x000D_
The cancer cachexiamarket covered in this report is segmented – _x000D_
_x000D_
1) By Therapeutics: Progestogens; Corticosteroids; Combination Therapies; Other Therapeutics_x000D_
2) By Mechanism Of Action: Appetite Stimulators; Weight Loss Stabilizers; Other Mechanisms Of Actions_x000D_
3) By Distribution Channel: Hospital Stores; Retail Pharmacy Stores; Online Pharmacies_x000D_
_x000D_
Subsegments:_x000D_
1) By Progestogens: Megestrol Acetate; Medroxyprogesterone Acetate; Hydroxyprogesterone Caproate _x000D_
2) By Corticosteroids: Dexamethasone; Prednisolone; Methylprednisolone _x000D_
3) By Combination Therapies: Progestogens + Corticosteroids; Progestogens + Anabolic Agents; Corticosteroids + Anabolic Agents _x000D_
4) By Other Therapeutics: Anabolic Agents; Appetite Stimulants; Anti-inflammatory Drugs; Nutritional Supplements_x000D_
_x000D_
#Request customized data on this market:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp_x000D_
_x000D_
#Which Areas Are Leading Regions in the Cancer Cachexia Market Expansion Across the Globe?#_x000D_
North America was the largest region in the cancer cachexia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#What Key Trends Are Shaping the Future of the Cancer Cachexia Market?#_x000D_
Leading companies in the cancer cachexia market are focusing on the creation of novel medications, including monoclonal antibodies for cachexia, with the goal of offering targeted therapies for this condition. This approach aims to enhance body weight, muscle mass, and overall life quality in patients affected by cachexia. The monoclonal antibodies aim to block factors promoting muscle and weight loss. For example, Pfizer Inc., an American pharmaceutical firm, revealed positive outcomes from its Phase 2 trial for Ponsegromab, a monoclonal antibody targeting GDF-15, for cachexia patients in September 2024. The trial demonstrated significant improvements in body weight, muscle mass, appetite, and physical activity levels, with the 400 mg dosage showing the best results. Encouraged by these optimistic results, Pfizer intends to launch studies that could potentially pave the way for the registration of Ponsegromab in 2025 to further explore its potential in treating cancer cachexia._x000D_
_x000D_
#View the full report here:#_x000D_
https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report_x000D_
_x000D_
#How Is the Cancer Cachexia Market Conceptually Defined?#_x000D_
Cancer cachexia is a complex metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, fatigue, and loss of appetite in individuals with cancer. It is a multifactorial condition resulting from a combination of factors such as inflammation, metabolic abnormalities, and the presence of tumors. Cancer cachexia can significantly impact a patient’s quality of life, impairing their ability to tolerate cancer treatments and reducing their overall survival._x000D_
_x000D_
#Purchase the full report and get a swift delivery:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15527_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Europe +44 7882 955267_x000D_
Asia & Others +44 7882 955267 & +91 8897263534_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model